PMC:7283670 / 54789-55409 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T337","span":{"begin":63,"end":71},"obj":"Disease"},{"id":"T338","span":{"begin":95,"end":103},"obj":"Disease"}],"attributes":[{"id":"A337","pred":"mondo_id","subj":"T337","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A338","pred":"mondo_id","subj":"T338","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"The efficacy and safety of huaier in the adjuvant treatment of COVID‐19 Drug: Huaier Granule COVID‐19 550, all, 18–75 Treatment Experimental group: standard therapy + Huaier granule 20 g, po, tid for 2 weeks (or until discharge)\nControl group: standard therapy II, III Primary (up to 28 days): all cause mortality\nSecondary (up to 28 days): clinical status, differences in oxygen intake methods, supplemental oxygenation, mechanical ventilation, mean PaO2/FiO2, length of hospital stay, Length of ICU stay (days), pulmonary function (up to 3 months after discharge) NCT04291053/Not yet recruiting, Apr1‐Sep1 2020"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T535","span":{"begin":115,"end":117},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"}],"text":"The efficacy and safety of huaier in the adjuvant treatment of COVID‐19 Drug: Huaier Granule COVID‐19 550, all, 18–75 Treatment Experimental group: standard therapy + Huaier granule 20 g, po, tid for 2 weeks (or until discharge)\nControl group: standard therapy II, III Primary (up to 28 days): all cause mortality\nSecondary (up to 28 days): clinical status, differences in oxygen intake methods, supplemental oxygenation, mechanical ventilation, mean PaO2/FiO2, length of hospital stay, Length of ICU stay (days), pulmonary function (up to 3 months after discharge) NCT04291053/Not yet recruiting, Apr1‐Sep1 2020"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T34382","span":{"begin":41,"end":49},"obj":"Chemical"},{"id":"T9718","span":{"begin":146,"end":151},"obj":"Chemical"},{"id":"T25818","span":{"begin":242,"end":247},"obj":"Chemical"},{"id":"T79148","span":{"begin":267,"end":269},"obj":"Chemical"},{"id":"T1524","span":{"begin":380,"end":386},"obj":"Chemical"}],"attributes":[{"id":"A30352","pred":"chebi_id","subj":"T34382","obj":"http://purl.obolibrary.org/obo/CHEBI_60809"},{"id":"A40244","pred":"chebi_id","subj":"T9718","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A86185","pred":"chebi_id","subj":"T25818","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A18780","pred":"chebi_id","subj":"T79148","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"},{"id":"A36720","pred":"chebi_id","subj":"T1524","obj":"http://purl.obolibrary.org/obo/CHEBI_25805"}],"text":"The efficacy and safety of huaier in the adjuvant treatment of COVID‐19 Drug: Huaier Granule COVID‐19 550, all, 18–75 Treatment Experimental group: standard therapy + Huaier granule 20 g, po, tid for 2 weeks (or until discharge)\nControl group: standard therapy II, III Primary (up to 28 days): all cause mortality\nSecondary (up to 28 days): clinical status, differences in oxygen intake methods, supplemental oxygenation, mechanical ventilation, mean PaO2/FiO2, length of hospital stay, Length of ICU stay (days), pulmonary function (up to 3 months after discharge) NCT04291053/Not yet recruiting, Apr1‐Sep1 2020"}

{"project":"LitCovid-sentences","denotations":[{"id":"T603","span":{"begin":0,"end":78},"obj":"Sentence"},{"id":"T604","span":{"begin":79,"end":233},"obj":"Sentence"},{"id":"T605","span":{"begin":234,"end":320},"obj":"Sentence"},{"id":"T606","span":{"begin":321,"end":620},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The efficacy and safety of huaier in the adjuvant treatment of COVID‐19 Drug: Huaier Granule COVID‐19 550, all, 18–75 Treatment Experimental group: standard therapy + Huaier granule 20 g, po, tid for 2 weeks (or until discharge)\nControl group: standard therapy II, III Primary (up to 28 days): all cause mortality\nSecondary (up to 28 days): clinical status, differences in oxygen intake methods, supplemental oxygenation, mechanical ventilation, mean PaO2/FiO2, length of hospital stay, Length of ICU stay (days), pulmonary function (up to 3 months after discharge) NCT04291053/Not yet recruiting, Apr1‐Sep1 2020"}

{"project":"LitCovid-PubTator","denotations":[{"id":"1806","span":{"begin":611,"end":615},"obj":"Gene"},{"id":"2093","span":{"begin":63,"end":71},"obj":"Disease"},{"id":"2094","span":{"begin":95,"end":103},"obj":"Disease"}],"attributes":[{"id":"A1806","pred":"tao:has_database_id","subj":"1806","obj":"Gene:1731"},{"id":"A2093","pred":"tao:has_database_id","subj":"2093","obj":"MESH:C000657245"},{"id":"A2094","pred":"tao:has_database_id","subj":"2094","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"The efficacy and safety of huaier in the adjuvant treatment of COVID‐19 Drug: Huaier Granule COVID‐19 550, all, 18–75 Treatment Experimental group: standard therapy + Huaier granule 20 g, po, tid for 2 weeks (or until discharge)\nControl group: standard therapy II, III Primary (up to 28 days): all cause mortality\nSecondary (up to 28 days): clinical status, differences in oxygen intake methods, supplemental oxygenation, mechanical ventilation, mean PaO2/FiO2, length of hospital stay, Length of ICU stay (days), pulmonary function (up to 3 months after discharge) NCT04291053/Not yet recruiting, Apr1‐Sep1 2020"}